<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(12)</volume><submitter>Elimian KO</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Despite the increasing disease burden, there is a dearth of context-specific evidence on the risk factors for COVID-19 positivity and subsequent death in Nigeria. Thus, the study objective was to identify context-specific factors associated with testing positive for COVID-19 and fatality in Nigeria.&lt;h4>Design&lt;/h4>Retrospective cohort study.&lt;h4>Setting&lt;/h4>COVID-19 surveillance and laboratory centres in 36 states and the Federal Capital Territory reporting data to the Nigeria Centre for Disease Control.&lt;h4>Participants&lt;/h4>Individuals who were investigated for SARS-CoV-2 using real-time PCR testing during the study period 27 February-8 June 2020.&lt;h4>Methods&lt;/h4>COVID-19 positivity and subsequent mortality. Multivariable logistic regression analyses were performed to identify factors independently associated with both outcome variables, and findings are presented as adjusted ORs (aORs) and 95% CIs.&lt;h4>Results&lt;/h4>A total of 36 496 patients were tested for COVID-19, with 10 517 confirmed cases. Of 3215 confirmed cases with available clinical outcomes, 295 died. Factors independently associated with COVID-19 positivity were older age (p value for trend&lt;0.0001), male sex (aOR 1.11, 95% CI 1.04 to 1.18) and the following presenting symptoms: cough (aOR 1.23, 95% CI 1.13 to 1.32), fever (aOR 1.45, 95% CI 1.45 to 1.71), loss of smell (aOR 7.78, 95% CI 5.19 to 11.66) and loss of taste (aOR 2.50, 95% CI 1.60 to 3.90). An increased risk of mortality following COVID-19 was observed in those aged ≥51 years, patients in farming occupation (aOR 7.56, 95% CI 1.70 to 33.53) and those presenting with cough (aOR 2.06, 95% CI 1.41 to 3.01), breathing difficulties (aOR 5.68, 95% CI 3.77 to 8.58) and vomiting (aOR 2.54, 95% CI 1.33 to 4.84).&lt;h4>Conclusion&lt;/h4>The significant risk factors associated with COVID-19 positivity and subsequent mortality in the Nigerian population are similar to those reported in studies from other countries and should guide clinical decisions for COVID-19 testing and specialist care referrals.</pubmed_abstract><journal>BMJ open</journal><pagination>e044079</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7747485</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study.</pubmed_title><pmcid>PMC7747485</pmcid><pubmed_authors>Ogunbode O</pubmed_authors><pubmed_authors>Ochu CL</pubmed_authors><pubmed_authors>Crawford EE</pubmed_authors><pubmed_authors>Mohammed AA</pubmed_authors><pubmed_authors>Aruna O</pubmed_authors><pubmed_authors>Olayinka A</pubmed_authors><pubmed_authors>Oladejo J</pubmed_authors><pubmed_authors>Mba N</pubmed_authors><pubmed_authors>Usman R</pubmed_authors><pubmed_authors>Usman M</pubmed_authors><pubmed_authors>Dan-Nwafor C</pubmed_authors><pubmed_authors>Olawepo OA</pubmed_authors><pubmed_authors>Nwadiuto I</pubmed_authors><pubmed_authors>Elimian KO</pubmed_authors><pubmed_authors>Venkatesan S</pubmed_authors><pubmed_authors>Ngishe S</pubmed_authors><pubmed_authors>Ukponu W</pubmed_authors><pubmed_authors>Myles P</pubmed_authors><pubmed_authors>Ebhodaghe B</pubmed_authors><pubmed_authors>Aderinola O</pubmed_authors><pubmed_authors>Yusuff HA</pubmed_authors><pubmed_authors>Ilori E</pubmed_authors><pubmed_authors>Abubakar I</pubmed_authors><pubmed_authors>Atteh R</pubmed_authors><pubmed_authors>Suleiman K</pubmed_authors><pubmed_authors>Obagha C</pubmed_authors><pubmed_authors>Ihekweazu C</pubmed_authors><pubmed_authors>Nwachukwu W</pubmed_authors><pubmed_authors>Igumbor E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study.</name><description>&lt;h4>Objective&lt;/h4>Despite the increasing disease burden, there is a dearth of context-specific evidence on the risk factors for COVID-19 positivity and subsequent death in Nigeria. Thus, the study objective was to identify context-specific factors associated with testing positive for COVID-19 and fatality in Nigeria.&lt;h4>Design&lt;/h4>Retrospective cohort study.&lt;h4>Setting&lt;/h4>COVID-19 surveillance and laboratory centres in 36 states and the Federal Capital Territory reporting data to the Nigeria Centre for Disease Control.&lt;h4>Participants&lt;/h4>Individuals who were investigated for SARS-CoV-2 using real-time PCR testing during the study period 27 February-8 June 2020.&lt;h4>Methods&lt;/h4>COVID-19 positivity and subsequent mortality. Multivariable logistic regression analyses were performed to identify factors independently associated with both outcome variables, and findings are presented as adjusted ORs (aORs) and 95% CIs.&lt;h4>Results&lt;/h4>A total of 36 496 patients were tested for COVID-19, with 10 517 confirmed cases. Of 3215 confirmed cases with available clinical outcomes, 295 died. Factors independently associated with COVID-19 positivity were older age (p value for trend&lt;0.0001), male sex (aOR 1.11, 95% CI 1.04 to 1.18) and the following presenting symptoms: cough (aOR 1.23, 95% CI 1.13 to 1.32), fever (aOR 1.45, 95% CI 1.45 to 1.71), loss of smell (aOR 7.78, 95% CI 5.19 to 11.66) and loss of taste (aOR 2.50, 95% CI 1.60 to 3.90). An increased risk of mortality following COVID-19 was observed in those aged ≥51 years, patients in farming occupation (aOR 7.56, 95% CI 1.70 to 33.53) and those presenting with cough (aOR 2.06, 95% CI 1.41 to 3.01), breathing difficulties (aOR 5.68, 95% CI 3.77 to 8.58) and vomiting (aOR 2.54, 95% CI 1.33 to 4.84).&lt;h4>Conclusion&lt;/h4>The significant risk factors associated with COVID-19 positivity and subsequent mortality in the Nigerian population are similar to those reported in studies from other countries and should guide clinical decisions for COVID-19 testing and specialist care referrals.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-26T04:21:48.583Z</modification><creation>2024-11-14T23:02:12.338Z</creation></dates><accession>S-EPMC7747485</accession><cross_references><pubmed>33334842</pubmed><doi>10.1136/bmjopen-2020-044079</doi></cross_references></HashMap>